DSI Zenoss Bone Matrix in Chips

Download brochure in PDF

DSI Zenoss Chips is a biocompatible bone mineral matrix and are manufactured from bovine bone according to a controlled and validated multistage purification process, while all organic components are removed.

A highly osteoconductive but slowly resorbed biomaterial. Zenoss Chips promote grafts that maintain structural integrity and sustain increasing vital bone formation over time. The long-term presence of Zenoss chips stabilizes the graft, leading to the retention of both volume and the desired form of augmented sites. Furthermore, bone mineral density is also increased.

As a result of this, grafted sites provide an ideal environment for long-term implant survival.

The inorganic bone matrix of DSI Zenoss Chips has macro-and microscopic structures similar to human bone. The formation and ingrowth of new bone at the implantation site is favoured due to its trabecular architecture and interconnecting macro and micropores. It maintains volume, reliably blocks the osteoclastic potential of periosteum and maxillary sinus mucosa (osteoclasts of hematogenous origin), prevents the ingrowth of soft tissue in the application area.


Augmentation or reconstructive treatment of the alveolar ridge
Filling of infrabony periodontal defects
Filling of defects after root resection, apicoectomy, and cystectomy
Filling of extraction sockets to enhance preservation of the alveolar ridge
Elevation of the maxillary sinus floor
Filling of periodontal defects in conjunction with products intended for Guided Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR)
Filling of peri-implant defects in conjunction with products intended for Guided Bone Regeneration (GBR)

Directions for Use:

The general principles of sterile handling and patient medication must be followed
The filling of periodontal defects with Zenoss graft requires successful treatment of the periodontal lesion (root planing, debridement) prior to the implantation. The defect should be covered with a membrane (e.g., DSI Zenoss Bio) for optimal tissue regeneration
After exposure of the bony defect with mucoperiosteal flap, all granulation tissue must be carefully removed
The material should be placed in direct contact with well-vascularized, bleeding bone surfaces. The cortical bone should be mechanically perforated to facilitate the ingrowth of new blood vessels and bone-forming cells
We suggest mixing DSI Zenoss chips with the patient’s blood or with physiological saline solution before the implantation. The chips are placed into the defect, using sterile instruments (spatula or spoon). The use of excessive force will result in the crushing of particles and loss of trabecular architecture
In situ modelling may be performed with a sterile spatula or other suitable instruments
Overfilling of the defects should be avoided
It is advisable to cover the graft with a membrane barrier (e.g., DSI Zenoss Bio)
When closing the wound, the soft tissue flap should completely cover the implanted graft and should be fixed by sutures (e.g. DSI PTFE)
If primary wound closure cannot be achieved, further mobilization of the flap (incision through the periosteum) should be performed
A surgical dressing may be placed over the wound for one to two weeks
Sites grafted with Zenoss Chips should be allowed to heal approximately 6 months prior to implant placement
A basic requirement for successful periodontal treatment includes control of any bacterial infection as well as thorough oral hygiene. It is advised that preceding the surgical intervention, there be a hygiene phase, which would include proper instruction for the patient. A postoperative maintenance phase can ensure long-term therapeutic success

ref code

Product Code
1.0cc, 1000-5000 µm ZGC40100
2.0cc, 1000-5000 µm ZGC40200